Biosimilar drugs appear comparable to brand-name counterparts August 08, 2016 By Tracey Walker Systematic review provides comprehensive first look at TNF-alpha biosimilar treatments. New bill aims to support generic, biosimilar drug competition July 06, 2016 By Christine Blank The CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development. Survey finds stakeholders lack understanding of biosimilars June 27, 2016 By Tracey Walker It is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report. Biosimilars uptake may lag for cancer patients, physicians June 09, 2016 By Bryant Furlow Biosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting? Arizona passes pharmacy biosimilar law June 02, 2016 By Christine Blank Arizona recently joined around 20 other states by passing a law allowing pharmacists to substitute certain interchangeable biosimilar drugs for brand name drugs. The biosimilar balance: More options, lower costs The fly in the ointment: CMS' current plan for HCPCS codes is a real buzz kill. Predictions for the future of high-cost specialty drugs April 25, 2016 By Mari Edlin IMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference. Biosimilars pose problems for Medicare beneficiaries April 25, 2016 By Christine Blank Surprisingly, Medicare beneficiaries are likely to pay much more for biosimilars than the referenced brand medication, according to a new report. Three drug trends impacting specialty pharmacy April 21, 2016 By Mari Edlin AMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching Addressing rising pharma costs: A roundtable discussion April 19, 2016 By Aubrey Westgate At the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.